News | May 24, 2024
Merck to showcase advances in the science of cancer with new data presented at ASCO 2024
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Establishing Asymchem’s first manufacturing footprint in Europe
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
_256_384.jpeg)
ASG Group of Eye Hospitals has 165+ branches in 85+ cities across India and abroad
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
The collaboration aims to bolster healthcare entrepreneurship
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
Subscribe To Our Newsletter & Stay Updated
